Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2007

Conference Call & Webcast Today at 10:00 CET

AMSTERDAM, August 29 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2007.


- Successful IPO, raising gross proceeds of EUR 55.7 million

- Cash & cash equivalents of EUR 56.3 million at June 30, 2007

- Exclusive license to all gene therapy products from CIMA, one of Europe's leading gene therapy centers

- U.S. FDA orphan drug designation for lead product AMT 011

- Positive results of Phase I/II in LPL type I deficiency

- Pre-registration trial commenced in Canada of AMT 011 in LPL deficiency

- Appointment of Ferdinand Verdonck as chairman of supervisory board.

- Global rights for our product AMT 020 for the treatment of acute intermittent porphyria

Results comparison

Total revenues for the six months ended June 30, 2007, were EUR 50,000 compared to EUR 208,000 for the same period in 2006. The decrease was primarily due to a decrease of government grants, since the grant project for LPL deficiency was completed in 2006.

The operating loss increased to EUR 7.2 million for the six months ended June 30, 2007, from EUR 4.2 million for the same period in 2006. This was primarily due to the increase of research & development costs to EUR 3.8 million for the six months ended June 30, 2007 from EUR 1.9 million in the same period of 2006. This increase is particularly related to the development work on the company's lead product AMT 011 for LPL deficiency and increased staffing. General and administrative costs rose primarily as a function of the higher number of staff employed, stock based compensation, increased facility expenses and advisory costs. These costs increased to EUR 3.5 million for the six months ended June 30, 2007, from EUR 2.6 million for the same period in 2006.

The net loss for the first six months was EUR 8.6 million, as compared to a net loss of EUR 3.2 million in the same period of 2006.

As of June 30, 2007, AMT had cash and cash equivalents of EUR 56.3 million, compared to EUR 14.1 million at December 31, 2006.

Recent events

Very recently AMT obtained an exclusive license from Digna Biotech to commercialize all gene therapy products resulting from the R&D activities performed at the Center for the Study of Applied Medicine (CIMA) at the University of Navarra, Spain. Employing more than 400 researchers, CIMA is one of the leading gene therapy research centers in Europe.

"AMT had an excellent first half of 2007, culminating in its listing on Euronext Amsterdam on June 20. The proceeds from this successful initial public offering will be used to accelerate our development programs and build up a marketing and sales infrastructure in anticipation of the expected commercial roll-out of our lead product in 2009. We expect to make considerable progress over the next 12 month related to our clinical programs and business development activities, and look forward to update our investors as these materialize," said Ronald Lorijn, CEO of AMT.

Conference call and webcast presentation

AMT will conduct a conference call open to the public today at 10.00 CET, which will also be webcast. Netherlands dial in: +31-(0)800-949- 4517 (toll free); US dial in: +1-866-291-4166 (toll free); UK dial in: +44- 207-107-0611. The webcast can be accessed on the investors portion of AMT's website at Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software. Playback of the call will be availably for 24 hours after the call. Dial in: +41-91-612-4330; +44-20-7108-6233; or +1-866-416-2558. The archived webcast also will be available for replay shortly after the close of the call.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy to become a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Condensed interim financial statements 30 June 2007

The attached consolidated income statement, balance sheet and cash flow statement are derived from our condensed interim financial statements 30 June 2007 which can be found on our website

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's reports filed from time to time with Euronext Amsterdam N.V.


Consolidated income statement

(In Euro x 1,000)

Period ended

30 June 2007 30 June 2006

Revenues - 52

Cost of sales - (42)

Gross profit - 10

Other income 50 198

Total net income 50 208

Research and development costs 3,790 1,871

General and administrative costs 3,486 2,559

Total operating costs 7,276 4,430

Operating result (7,226) (4,222)

Interest income 230 7

Interest costs (1,644) (51)

(1,414) (44)

Result on deconsolidation - 1,113

Result before corporate income taxes (8,640) (3,153)

Corporate income taxes - -

Result for the period (8,640) (3,153)

Attributable to:

Equity holders of the Company (8,640) (3,153)

Earnings per share for result

attributable to the equity holders of the

Company during the period

(expressed in Euro per share)

Basic and diluted earnings per share (0.97) (1.61)


Consolidated balance sheet

(after appropriation of result)

(In Euro x 1,000)

30 June 31 December

2007 2006


Non current assets

Intangible assets 1,540 1,540

Property, plant and equipment 1,463 1,091

3,003 2,631

Current assets

Receivables from related parties 862 1,202

Social security and other taxes 178 276

Other receivables 290 51

Cash and cash equivalents 56,283 14,058

57,613 15,587

Total assets 60,616 18,218


Shareholders' equity 52,260 (1,682)

Total group equity 52,260 (1,682)


Non-current liabilities

Loan from related party - 1,038

Liabilities to preference shareholders - 15,504

Financial lease liabilities 445 498

Other non-current liabilities 903 45

1,348 17,085

Current liabilities

Trade payables 674 963

Payables to related parties 1,857 266

Social security and other taxes 186 153

Other current liabilities 4,291 1,433

7,008 2,815

Total liabilities 8,356 19,900

Total equity and liabilities 60,616 18,218


Consolidated cash flow statement

(In Euro x 1,000)

Period ended

30 June 30 June

2007 2006

Cash flow from operating


Result before corporate income

tax (8,640) (3,153)

Adjustments for:

- Depreciation 134 118

- Share based payment expenses 1,543 79

- Gain on derecognition financial

lease (53) -

- Re-purchase of EMT sales rights - 1,736

- Gain on deconsolidation AVP - (1,113)

- Changes in working capital 2,767 316

- Interest income/ (expense) 1,414 76

Cash generated from operations

(2,835) (1,941)

Interest paid

- (15)

Net cash generated from operating

activities (2,835) (1,956)

Cash flows from investing


Purchases of property, plant and

equipment (505) (66)

Proceeds from sale of property,

plant and equipment

- -

Purchases of intangible fixed

assets - -

Interest received 230 7

Net cash received in investing

activities (275) (59)

Cash flow from financing


Proceeds from issuance of loans - 200

Capital contribution shareholders 45,335 -

Net cash used in financing

activities 45,335 233

Net (decrease)/ increase in cash,

cash equivalents

and bank overdrafts 42,225 (1,815)

Cash, cash equivalents and bank


In the beginning of the period 14,058 521

Cash, cash equivalents at the end

of the period

56,283 (1,294)

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Detect Single Nucleotide Sequence Changes with Mx4000 Molecular Beacon Allelic Discrimination Kits
2. Genotyping Single Nucleotide Polymorphisms with Molecular Beacons
3. New Protocols for Isolating High- Molecular-Weight Genomic DNA
4. HSVision Molecular Beacon Detection Module Rapidly Detects Herpes Simplex Virus DNA
5. Molecular Biology:Easy Dephosphorylation and Rapid DNA Ligation
6. Isolation of Low Molecular Weight Digestion Products of the Human Platelet Thromboxane A2 Receptor, Rev A
7. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
8. Measurement of proteasome inhibition in live cells in Molecular Devices microplate fluorometers
9. Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36)
10. Kodak in vivo imaging system: precise coregistration of molecular imaging with anatomical X-ray imaging in animals
11. Near Infrared Technology and Optical Agents For Molecular Imaging
Post Your Comments:
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
Breaking Biology Technology:
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
Breaking Biology News(10 mins):